**REGISTERED CHARITY NUMBER: 1026791** 

## **TRUSTEES' REPORT AND** 

**UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024** 

**FOR GUTS (GUILDFORD UNDETECTED TUMOUR SCREENING)** 

Centora James Limited Jury Farm Ripley Lane West Horsley KT24 6JT 



**GUTS (GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024** 

||**Page**|
|---|---|
|**Trustees' Report**|1 to 3|
|**Independent Examiner's Report**|4|
|**Statement of Financial Ac�vi�es**|5|
|**Balance Sheet**|6|
|**Notes to the Financial Statements**|7 to 11|
|**Detailed Statement of Financial Ac�vi�es**|12 to 13|





**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **TRUSTEES' REPORT** 

## **FOR THE YEAR ENDED 31 MARCH 2024** 

## **INTRODUCTION** 

In the United Kingdom, around 18,000 people die from colon cancer every year.  Many of those deaths could be prevented by earlier diagnosis.  People over 50 and anyone with a history of colon cancer in the family, who experience changes in their bowel habit, are par�cularly at risk.  GUTS was set up in 1983 with the stated purpose of improving the early detec�on of bowel cancer. The charity established one of the first local popula�on screening programmes for bowel cancer, working with GP prac�ces in Surrey, West Sussex and Hampshire.  In 2006 a Bowel Cancer Screening Programme was set up in England and, with the ac�ve and financial support of GUTS, the centre for the South of England was based in Guildford.  This programme currently offers screening to everyone between the ages 56 and 74, and is available, on request, beyond 74 years of age. The programme is currently being extended to ages 50-74.  For those outside this age range, GUTS con�nues to advise families and others at risk, through its Colorectal Cancer Family Clinic. 

## **ORGANISATION STRUCTURE, GOVERNANCE AND MANAGEMENT OF THE CHARITY** 

The Trust is an unincorporated body set up by Trust Deed dated 7th September 1993 as amended on 5 December 2007, and is a registered charity.  The current Trustees are set out on Page 1.  Trustees are required to administer the charitable trust in accordance with the Trust Deed and conform to the requirements of the Charity Commission and Inland Revenue.  The day-to-day management of the Trust lies with the Execu�ve Commi�ee and Fundraising Commi�ee, details of which are set out below.  The Trust Deed requires there to be at least three Trustees.  All trustees shall, by virtue of his or her personal or professional qualifica�ons, be able to make a contribu�on to the pursuit of the objects or the management of the charity. 

Mr Iain Jourdan FRCS - Chairman and director of all medical ma�ers Mr J F Stebbing - Medical ma�ers Mr M Sharpe - Finance and regulatory ma�ers 

The induc�on process for any new Trustee comprises an ini�al mee�ng with the Chairman, followed by mee�ngs with no less than two other Trustees.  A new Trustee would be appointed by a resolu�on of the Trustees passed at a special mee�ng, a�er the new Trustee has signed a declara�on of their acceptance and willingness to act in the interests of the charity.  New Trustees are provided with a pack comprising a copy of the Trust Deed, the last financial year’s annual report and accounts, and a copy of the Charity Commission booklets “The Essen�al Trustee”. 

systems and procedures are in place to manage those risks. 

## **GUTS Commi�ee Structure** 

The Execu�ve Commi�ee, currently chaired by Mr Iain Jourdan, shall comprise the Trustees, Treasurer and Fundraising Coordinator and be responsible for policy, funding and charitable expenditure, staffing, legal and financial ma�ers. 

## **Execu�ve Commi�ee Members (at 31 March 2024)** 

Mr Iain Jourdan (Chairman from 1 June 2010) Mr Andrea Scala (Trustee) Phill Davis (Trustee) Mr John Stebbing (Trustee) Dena Dixon (Trustee) Ma� Sharpe (Treasurer & Trustee) Prof S P Halloran (Trustee) Chris�an Wells (Trustee) Mr James Read (Trustee) Jayne White (Trustee) Prof T A Rockall (Trustee) Nerissa Deeks (Fundraising Manager) 

## **OPERATIONAL PERSONNEL** 

## **Management of the Family Cancer Clinic** 

Nicola Hounsham administers the GUTS Family Cancer Clinic, providing counselling and screening to families with a history of cancer. This clinic is wholly funded by GUTS. 

## **Fundraising** 

Nerissa Deeks is responsible for coordina�ng fundraising and day-to-day running of the charity, with part-�me help from Joe Smith. 

## **Treasurer** 

ma�ers. 

Page 1 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **TRUSTEES' REPORT** 

## **FOR THE YEAR ENDED 31 MARCH 2024** 

## **OBJECTIVES AND ACTIVITIES FOR THE PUBLIC BENEFIT** 

The formal objec�ves of GUTS are: 

“the preserva�on and protec�on of good health by screening and undertaking or assis�ng in the undertaking of research for the early detec�on and treatment of cancer and other diseases of the diges�ve system and the publica�on of the useful results of such research.” 

GUTS works towards these objec�ves by funding: 

- The Colorectal Family Cancer Clinic which offers counselling and screening regimes for people at moderate/high risk of developing bowel cancer by virtue of a strong family history. 

- Clinical and research projects where the researchers’ areas of interest further the objects of the charity. 

- Dona�ng appropriate medical equipment as and when the need arises and when alterna�ve sources of funding are not readily available. 

benefit when reviewing the Trust’s aims and objec�ves and when planning future ac�vi�es and se�ng the grant making policies for the year. 

## **ACHIEVEMENTS, PERFORMANCE AND FUTURE DEVELOPMENTS** 

## **Colorectal Cancer Family Clinic** 

The GUTS Colorectal Family clinic con�nues to provide appropriate advice to individuals with a family history of bowel cancer, applying na�onal referral guidelines overseen by surgeons and gastroenterologists at the Royal Surrey County Hospital. Individuals at low or low/moderate risk receive wri�en advice including recommenda�ons for future screening.  Individuals at high/moderate or high risk are offered a clinic appointment for risk assessment, counselling and screening. Gene�c tes�ng is made available to iden�fy inherited condi�ons within families that may have a high risk of developing colorectal cancers. 

## **Suppor�ng Research** 

**Papillon Colorectal Database:** GUTS is working with the charity ‘Bright’ on this project. Thanks to funding from GUTS, amoun�ng to an annual grant of £31,000, a computer scien�st is now working to redesign the database to improve its func�onality and progress it to the next stage which is to build a central bank of informa�on based on pa�ent experience (PROMS). The project is known as the CITRuS Study. Although the study was originally designed for people treated with Papillon radiotherapy it has now been extended to include other bowel cancer pa�ents. 

During this period the second stage of the project began. This involved the recruitment of pa�ents willing to complete ques�onnaires before, during, and at the end of their treatment. These ques�onnaires are designed to gauge the range of symptoms and side-effects that pa�ents experience at different stages of their treatment and recovery. 

The data collected from the ques�onnaires will be used to inform and prepare new pa�ents as they begin treatment. Eventually, pa�ents will be able to log into a portal in order to access informa�on and advice regarding their treatment and self-management of symptoms and side-affects. 

**R-FIT Study:** Southern Bowel Cancer Screening Hub and completed in 2023. The purpose of the study was to determine the effec�veness of repeated FIT tests on symptoma�c pa�ents. (FIT, the faecal immunochemical test, is the interna�onally adopted bowel cancer screening test for popula�on screening and is used in the UK). 

460 symptoma�c pa�ents were recruited to the study, each returning three FIT tests. Nega�ve FIT results were compared with posi�ve cohorts. The results showed that a repeat FIT strategy provides greater differen�a�on and improved cancer/significant bowel pathology detec�on compared to one FIT.  Repeat FIT therefore offers a safe, cost-effec�ve strategy for triaging symptoma�c pa�ents and is less invasive and more accurate than a follow-up colonoscopy a�er just one posi�ve FIT test. 

**Support for pa�ents at the end of treatment:** During this period trustees discussed the need for more support for pa�ents reaching the end of their treatment. As a result of their treatment for bowel cancer, pa�ents o�en experience legacy symptoms that can be difficult to manage and have other psychological/social issues to deal with too. There is currently very li�le support for this area, and trustees agreed that more should be done. The star�ng point would be a new GUTS website that could provide more detailed informa�on and signpos�ng, presented in a user-friendly way. Further plans for delivering face-to-face support for such pa�ents are in development, working with nursing colleagues and other interested groups within the hospital. 

Page 2 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **TRUSTEES' REPORT** 

## **FOR THE YEAR ENDED 31 MARCH 2024** 

**Fundraising:** anniversary was deployed to increase fundraising ac�vi�es over the year, beginning with a ball. A succession of celebratory events throughout the year, coupled with some fortunate legacies and large dona�ons put the charity finances back on an even keel. Such was the turnaround that the Treasurer said the charity should find more projects to support so that the monies raised could be used more immediately, as intended by donors and supporters. 

## **INVESTMENT POLICY AND PERFORMANCE ACHIEVED AGAINST THE POLICY** 

Equity market.  The performance has broadly matched the movement in that market. 

## **RESERVES POLICY** 

The Trust’s charitable ac�vi�es include the development and maintenance of a cancer screening and counselling service, and the financing of cancer research over a number of con�guous areas which, to be effec�ve, requires a commitment to funding over the medium term.  Having regard to this, Trustees have established a policy whereby unrestricted funds, not commi�ed or invested in tangible fixed assets (the free reserves), should be maintained at a level sufficient to finance around two years’ charitable expenditure. 

## **ETHICAL POLICY** 

The ethical policy adopted and published by GUTS is based on principles recommended by the Na�onal Council for Voluntary Organisa�ons (NCVO), of which GUTS is a member.  GUTS conducts its affairs as far as possible in accordance with those principles. 

## **ACKNOWLEDGEMENTS** 

The Trustees wish to place on record that they are grateful to the many GUTS supporters who do so much to make our work possible. 

**REFERENCE AND ADMINISTRATIVE DETAILS Registered Charity number** 1026791 

## **Principal address** 

Royal Surrey NHS Founda�on Trust Egerton Road Guildford Surrey GU2 7XX 

## **Independent Examiner** 

K D N De Silva Centora James Limited Jury Farm Ripley Lane West Horsley KT24 6JT 

Approved by order of the board of trustees on 31 January 2025 and signed on its behalf by: 

Mr I Jourdan Chair of the Trustees 

Page 3 



**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **Independent examiner's report to the trustees of GUTS (Guildford Undetected Tumour Screening)** 

I report to the charity trustees on my examina�on of the accounts of GUTS (Guildford Undetected Tumour Screening) (the Trust) for the year ended 31 March 2024. 

## **Responsibili�es and basis of report** 

As the charity trustees of the Trust you are responsible for the prepara�on of the accounts in accordance with the requirements of the Chari�es Act 2011 ('the Act'). 

I report in respect of my examina�on of the Trust's accounts carried out under Sec�on 145 of the Act and in carrying out my examina�on I have followed all applicable Direc�ons given by the Charity Commission under Sec�on 145(5)(b) of the Act. 

## **Independent examiner's statement** 

qualified to undertake the examina�on because I am a member of the Associa�on of Chartered Cer�fied Accountants, which is one of the listed bodies. 

giving me cause to believe that in any material respect: 

1. accoun�ng records were not kept in respect of the Trust as required by Sec�on 130 of the Act; or 

2. the accounts do not accord with those records; or 

3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Chari�es (Accounts and Reports) Regula�ons 2008 other than any requirement that the accounts give a true and fair view which is not a ma�er considered as part of an independent examina�on. 

I have no concerns and have come across no other ma�ers in connec�on with the examina�on to which a�en�on should be drawn in this report in order to enable a proper understanding of the accounts to be reached. 

K D N De Silva 

Centora James Limited Jury Farm Ripley Lane West Horsley KT24 6JT 

Date: 31 January 2025 

Page 4 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2024** 

|||31.3.24|31.3.23|
|---|---|---|---|
|||Unrestricted|Total|
|||fund|funds|
||Notes|£|£|
|**INCOME AND ENDOWMENTS FROM**||||
|Dona�ons and legacies||259,250|26,657|
|Other trading ac�vi�es|2|63,041|15,705|
|Investment income|3|48,317|36,508|
|**Total**||370,608|78,870|
|**EXPENDITURE ON**||||
|Raising funds|4|92,525|55,183|
|**Charitable ac�vi�es**||||
|General||33,795|56,879|
|Support costs||6,456|8,769|
|Other||605|481|
|**Total**||133,381|121,312|
|Net gains/(losses) on investments||1,900|(66,289)|
|**NET INCOME/(EXPENDITURE)**||239,127|(108,731)|
|**RECONCILIATION OF FUNDS**||||
|Total funds brought forward||520,883|629,614|
|**TOTAL FUNDS CARRIED FORWARD**||760,010|520,883|



Page 5 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **BALANCE SHEET 31 MARCH 2024** 

|Notes<br>**FIXED ASSETS**<br>Tangible assets<br>7<br>Investments<br>8<br>**CURRENT ASSETS**<br>Debtors<br>9<br>Cash at bank and in hand<br>**CREDITORS**<br>Amounts falling due within one year<br>10<br>**NET CURRENT ASSETS**<br>**TOTAL ASSETS LESS CURRENT LIABILITIES**<br>**NET ASSETS**<br>**FUNDS**<br>11<br>Unrestricted funds<br>**TOTAL FUNDS**|31.3.24<br>Unrestricted<br>fund<br>£<br>272<br>487,863<br>488,135<br>9,425<br>268,756<br>278,181<br>(6,306)<br>271,875<br>760,010<br>760,010<br>760,010<br>760,010|31.3.23<br>Total<br>funds<br>£<br>363<br>454,797|
|---|---|---|
|||455,160<br>9,240<br>61,197|
|||70,437<br>(4,714)|
|||65,723|
|||520,883|
|||520,883|
|||520,883|
|||520,883|



its behalf by: 

Mr I Jourdan Chair of the Trustees 

Page 6 



**GUTS (GUILDFORD UNDETECTED TUMOUR SCREENING)** 

**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024** 

## **1. ACCOUNTING POLICIES** 

## 

with the Chari�es SORP (FRS 102) 'Accoun�ng and Repor�ng by Chari�es: Statement of Recommended Prac�ce applicable to chari�es preparing their accounts in accordance with the Financial Repor�ng Standard applicable in the UK and Republic of Ireland (FRS 102) (effec�ve 1 January 2019)', Financial Repor�ng Standard 102 'The Financial Repor�ng Standard applicable in the UK and Republic of Ireland' and the Chari�es Act 2011. The financial statements have been prepared under the historical cost conven�on, with the excep�on of investments which are included at market value. 

## **Income** 

All income is recognised in the Statement of Financial Ac�vi�es once the charity has en�tlement to the funds, it is probable that the income will be received and the amount can be measured reliably. 

## **Expenditure** 

Liabili�es are recognised as expenditure as soon as there is a legal or construc�ve obliga�on commi�ng the charity to that expenditure, it is probable that a transfer of economic benefits will be required in se�lement and the amount of the obliga�on can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly a�ributed to par�cular headings they have been allocated to ac�vi�es on a basis consistent with the use of resources. 

accrued as expenditure. 

## 

Plant and machinery -  25% on reducing balance Fixtures and fi�ngs -  33% on cost Motor vehicles -  25% on reducing balance 

## **Taxa�on** 

The charity is exempt from tax on its charitable ac�vi�es. 

## **Fund accoun�ng** 

Unrestricted funds can be used in accordance with the charitable objec�ves at the discre�on of the trustees. 

Restricted funds can only be used for par�cular restricted purposes within the objects of the charity.  Restric�ons arise when specified by the donor or when funds are raised for par�cular restricted purposes. 

## 

charged to the  Statement of Financial Ac�vi�es in the period to which they relate. 

con�nued… 

Page 7 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **NOTES TO THE FINANCIAL STATEMENTS - con�nued FOR THE YEAR ENDED 31 MARCH 2024** 

## **2. OTHER TRADING ACTIVITIES** 

|**2.**|**OTHER TRADING ACTIVITIES**|||
|---|---|---|---|
|||31.3.24|31.3.23|
|||£|£|
||Fundraising events|63,041|15,705|
|**3.**|**INVESTMENT INCOME**|||
|||31.3.24|31.3.23|
|||£|£|
||Other fxed asset invest - FII|48,127|36,446|
||Deposit account interest|190|62|
|||48,317|36,508|
|**4.**|**RAISING FUNDS**|||
||**Raising dona�ons and legacies**|||
|||31.3.24|31.3.23|
|||£|£|
||Staf costs|39,888|36,785|
||Cost of events|20,457|7,726|
||Adver�sing|2,255|3,865|
||Website costs|22,880|-|
|||85,480|48,376|
||**Investment management costs**|||
|||31.3.24|31.3.23|
|||£|£|
||Por�olio management|7,045|6,807|
||Aggregate amounts|92,525|55,183|



## **5. TRUSTEES' REMUNERATION AND BENEFITS** 

31 March 2023. 

## **Trustees' expenses** 

There were no trustees' expenses paid for the year ended 31 March 2024 nor for the year ended 31 March 2023. 

con�nued… 

Page 8 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **NOTES TO THE FINANCIAL STATEMENTS - con�nued** 

## **FOR THE YEAR ENDED 31 MARCH 2024** 

## **6. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES** 

||||||Unrestricted|
|---|---|---|---|---|---|
||||||fund|
||||||£|
||**INCOME AND ENDOWMENTS FROM**|||||
||Dona�ons and legacies||||26,657|
||Other trading ac�vi�es||||15,705|
||Investment income||||36,508|
||**Total**||||78,870|
||**EXPENDITURE ON**|||||
||Raising funds||||55,183|
||**Charitable ac�vi�es**|||||
||General||||56,879|
||Support costs||||8,769|
||Other||||481|
||**Total**||||121,312|
||Net gains/(losses) on investments||||(66,289)|
||**NET INCOME/(EXPENDITURE)**||||(108,731)|
||**RECONCILIATION OF FUNDS**|||||
||Total funds brought forward||||629,614|
||**TOTAL FUNDS CARRIED FORWARD**||||520,883|
|**7.**|**TANGIBLE FIXED ASSETS**|||||
||||Fixtures|||
|||Plant and|and|Motor||
|||machinery|f�ngs|vehicles|Totals|
|||£|£|£|£|
||**COST**|||||
||At 1 April 2023 and 31 March 2024|307|644|13,250|14,201|
||**DEPRECIATION**|||||
||At 1 April 2023|259|644|12,935|13,838|
||Charge for year|12|-|79|91|
||At 31 March 2024|271|644|13,014|13,929|
||**NET BOOK VALUE**|||||
||At 31 March 2024|36|-|236|272|
||At 31 March 2023|48|-|315|363|



con�nued… 

Page 9 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **NOTES TO THE FINANCIAL STATEMENTS - con�nued FOR THE YEAR ENDED 31 MARCH 2024** 

## **8. FIXED ASSET INVESTMENTS** 

|**MARKET VALUE**<br>At 1 April 2023<br>Addi�ons<br>At 31 March 2024<br>**NET BOOK VALUE**<br>At 31 March 2024<br>At 31 March 2023<br>There were no investment assets outside the UK.<br>**9.**<br>**DEBTORS**<br>Amounts falling due within one year:<br>Other debtors<br>Prepayments<br>Amounts falling due a�er more than one year:<br>Trade debtors<br>Aggregate amounts<br>**10.**<br>**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**<br>Taxa�on and social security<br>Other creditors<br>**11.**<br>**MOVEMENT IN FUNDS**<br>**Unrestricted funds**<br>General fund<br>**TOTAL FUNDS**|Listed<br>investments<br>£<br>454,797<br>33,066<br>487,863<br>487,863<br>454,797<br>31.3.24<br>31.3.23<br>£<br>£<br>190<br>650<br>1,011<br>-<br>1,201<br>650<br>8,224<br>8,590<br>9,425<br>9,240<br>31.3.24<br>31.3.23<br>£<br>£<br>2,708<br>1,130<br>3,598<br>3,584<br>6,306<br>4,714<br>Net<br>movement<br>At<br>At 1.4.23<br>in funds<br>31.3.24<br>£<br>£<br>£<br>520,883<br>239,127<br>760,010<br>520,883<br>239,127<br>760,010|Listed<br>investments<br>£<br>454,797<br>33,066<br>487,863<br>487,863<br>454,797<br>31.3.24<br>31.3.23<br>£<br>£<br>190<br>650<br>1,011<br>-<br>1,201<br>650<br>8,224<br>8,590<br>9,425<br>9,240<br>31.3.24<br>31.3.23<br>£<br>£<br>2,708<br>1,130<br>3,598<br>3,584<br>6,306<br>4,714<br>Net<br>movement<br>At<br>At 1.4.23<br>in funds<br>31.3.24<br>£<br>£<br>£<br>520,883<br>239,127<br>760,010<br>520,883<br>239,127<br>760,010|
|---|---|---|
|||487,863|
|||487,863|
|||454,797|
|||31.3.23<br>£<br>650<br>-<br>650<br>8,590<br>9,240<br>31.3.23<br>£<br>1,130<br>3,584<br>4,714<br>At<br>31.3.24<br>£<br>760,010|
|||760,010|



con�nued... 

Page 10 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **NOTES TO THE FINANCIAL STATEMENTS - con�nued FOR THE YEAR ENDED 31 MARCH 2024** 

## **11. MOVEMENT IN FUNDS - con�nued** 

Net movement in funds, included in the above are as follows: 

|**Unrestricted funds**<br>General fund<br>**TOTAL FUNDS**|Incoming<br>Resources<br>resources<br>expended<br>£<br>£<br>370,608<br>(133,381)<br>370,608<br>(133,381)|Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>1,900<br>239,127<br>1,900<br>239,127|Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>1,900<br>239,127<br>1,900<br>239,127|
|---|---|---|---|
||||239,127|



## **Compara�ves for movement in funds** 

|**Unrestricted funds**<br>General fund<br>**TOTAL FUNDS**|Net<br>movement<br>At 1.4.22<br>in funds<br>£<br>£<br>629,614<br>(108,731)<br>629,614<br>(108,731)|At<br>31.3.23<br>£<br>520,883|
|---|---|---|
|||520,883|



Compara�ve net movement in funds, included in the above are as follows: 

|**Unrestricted funds**<br>General fund<br>**TOTAL FUNDS**|Incoming<br>Resources<br>resources<br>expended<br>£<br>£<br>78,870<br>(121,312)<br>78,870<br>(121,312)|Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>(66,289)<br>(108,731)<br>(66,289)<br>(108,731)|Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>(66,289)<br>(108,731)<br>(66,289)<br>(108,731)|
|---|---|---|---|
||||(108,731)|



## **12. RELATED PARTY DISCLOSURES** 

There were no related party transac�ons for the year ended 31 March 2024. 

Page 11 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2024** 

|**DETAILED STATEMENT OF FINANCIAL ACTIVITIES**<br>**FOR THE YEAR ENDED 31 MARCH 2024**|||
|---|---|---|
||31.3.24|31.3.23|
||£|£|
|**INCOME AND ENDOWMENTS**|||
|**Dona�ons and legacies**|||
|Dona�ons|43,218|23,157|
|Legacies|216,032|3,500|
||259,250|26,657|
|**Other trading ac�vi�es**|||
|Fundraising events|63,041|15,705|
|**Investment income**|||
|Other fxed asset invest - FII|48,127|36,446|
|Deposit account interest|190|62|
||48,317|36,508|
|**Total incoming resources**|370,608|78,870|
|**EXPENDITURE**|||
|**Raising dona�ons and legacies**|||
|Wages|39,007|35,960|
|Pensions|881|825|
|Cost of events|20,457|7,726|
|Adver�sing|2,255|3,865|
|Website costs|22,880|-|
||85,480|48,376|
|**Investment management costs**|||
|Por�olio management|7,045|6,807|
|**Charitable ac�vi�es**|||
|Medical staf salaries|5,568|5,568|
|Grants to ins�tu�ons|28,220|51,311|
|Grants to individuals|657|-|
||34,445|56,879|
|**Other**|||
|Bank Fees|605|481|



Page 12 



**GUTS** 

**(GUILDFORD UNDETECTED TUMOUR SCREENING)** 

## **DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2024** 

|**DETAILED STATEMENT OF FINANCIAL ACTIVITIES**<br>**FOR THE YEAR ENDED 31 MARCH 2024**|||
|---|---|---|
||31.3.24|31.3.23|
||£|£|
|**Support costs**|||
|**Governance costs**|||
|Insurance|722|1,683|
|Postage and sta�onery|200|1,199|
|Sundries|855|633|
|Accountancy and legal fees|2,940|3,120|
|Motor Vehicle Expenses|872|1,892|
|IT so�ware and consumables|47|-|
|Telephone|79|-|
|Plant and machinery|12|32|
|Motor vehicles|79|210|
||5,806|8,769|
|Total resources expended|133,381|121,312|
|**Net income/(expenditure) before gains and losses**|237,227|(42,442)|
|**Realised recognised gains and losses**|||
|Realised gains/(losses) on investment property|1,900|(66,289)|
|**Net income/(expenditure)**|239,127|(108,731)|



Page 13